28-MAR-2026 6:10

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O 1 Y 1 Delayed V-O 247 63 14 9 3 1 0 03/02/2021 277 94
        2 Early V-O   116 26 13 6 2 1      
            179 40 22 9 3 1      
 
  MM1OA-S03-AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena 1 Y 1 ASTX727 + Venetoclax + Enasidenib (Safety Run-in) 102 8 8 2 0 0 0 05/16/2025 213 59
            8 8 2 0 0 0      
 
  MM1YA-S01-AML, High Risk, Age <60, 7+3 vs experimental 1 Y 1 Daunorubicin + Cytarabine 335 13 10 3 2 0 0 09/25/2024 304 105
        2 Venetoclax + Daunorubicin + Cytarabine   12 9 4 2 2 0      
        3 Venetoclax + Azacitidine   13 11 5 1 0 0      
        4 (Daunorubicin + Cytarabine) Liposome   14 11 5 2 1 1      
        5 (Daunorubicin + Cytarabine) Liposome + Venetoclax   12 10 4 4 1 0      
            64 51 21 11 4 1      
 
  MYELOMATCH-MSRP for the NCI myeloMATCH Clinical Trials 1 Y 1 Screening   1008 610 298 147 52 12 06/18/2024 368 139
            1008 610 298 147 52 12      
 
    2 Y 2 Re-screening   113 75 54 38 18 8 06/18/2024    
            113 75 54 38 18 8      
 
    3 Y 3 Re-screening   30 27 19 10 3 1 06/18/2024    
            30 27 19 10 3 1      
 
    4 Y 4 Re-screening   2 1 1 0 0 0 06/18/2024    
            2 1 1 0 0 0      
 
Yes EA9213-T-ALL, dara-hyal for chemo refractory MRD 0 E Total Registrations   8 2 2 2 1 1 02/24/2023 115 39
            8 2 2 2 1 1      
 
    1 E Total Registrations   3 0 0 0 0 0 02/24/2023    
            3 0 0 0 0 0      
 
No A041501-B-Cell ALL, Frontline Tx +/- Intuzumab Ozo 0 E Total Registrations   73 2 2 2 2 0 11/09/2018 285 87
            73 2 2 2 2 0      
 
    1 E Total Registrations   58 1 1 1 1 0 11/09/2018    
            58 1 1 1 1 0      
 
    2 E Total Registrations   44 0 0 0 0 0 11/09/2018    
            44 0 0 0 0 0      
 
  A041703-ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat 0 E Total Registrations   11 0 0 0 0 0 08/13/2020 164 45
            11 0 0 0 0 0      
 
    1 E Total Registrations   5 0 0 0 0 0 08/13/2020    
            5 0 0 0 0 0      
 
  EA9181-ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 0 E Total Registrations   66 15 7 2 0 0 02/19/2021 194 58
            66 15 7 2 0 0      
 
    1 E Total Registrations   54 12 6 2 0 0 02/19/2021    
            54 12 6 2 0 0      
 
    2 E Total Registrations   48 12 6 3 1 0 02/19/2021    
            48 12 6 3 1 0      
 
  MM1OA-EA02-MyeloMATCH: AML, New Dx, Ven+HMA 1 E Total Registrations   17 14 8 4 1 1 12/02/2024 304 101
            17 14 8 4 1 1      
 
  MM1YA-CTG01-MyeloMATCH: AML, New/Young/Int, Ven+Chemo 1 E Total Registrations   8 6 3 2 0 0 10/14/2024 37 7
            8 6 3 2 0 0      
 

28-MAR-2026 6:10

LEUK Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
21CTP.LEUK01 ALL, Ph+, Asciminib, Dasatinib and Prednisone 1 Initial Registration 15-May-25    
  2 Post-Remission 15-May-25    
  3 Maintenance 15-May-25    

28-MAR-2026 6:10

LEUK Recently Closed Studies Accrual Report

OPEN Study Date
Closed		 Reg. Arm Total
Regs		 Regs
Last
30 Days		 Regs
Last
7 Days
E EA9181-ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 26-Mar-26 0 Total Registrations 66 0 0
      1 Total Registrations 54 0 0
      2 Total Registrations 48 1 0
      3 Total Registrations 1 0 0